Save up -80% on Coagulation factor VIIa Recombinant
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Novoseven RT
|$2,227.65||1 kit (1 vial) 1mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Novoseven RT coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Coagulation factor VIIa Recombinant every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Coagulation factor VIIa Recombinant volume of distribution
Measured in plasma drawn prior to and during a 24-hour period after NovoSeven administration. The median apparent volume of distribution at steady state was 103 mL/kg (range 78-139).
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Coagulation factor VIIa Recombinant
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Coagulation factor VIIa Recombinant mechanism of action
NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Dosage forms of Coagulation factor VIIa Recombinant
|Powder for solution||intravenous||1.2 mg|
|Powder for solution||intravenous||2.4 mg|
|Powder for solution||intravenous||4.8 mg|
Coagulation factor VIIa Coagulation factor VIIa (recombinant)
Novo Nordisk Canada Inc
Humans and other mammals
Indication of Coagulation factor VIIa Recombinant
For treatment of hemorrhagic complications in hemophilia A and B
Toxicity of Coagulation factor VIIa Recombinant
A large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Coagulation factor VIIa Recombinant on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.